Evidence map›Paper›PMID 41784806›Full record

ReviewZeitschrift fur Rheumatologie2026

Combination therapy with mycophenolate mofetil, nintedanib, and tocilizumab in a patient with progressive systemic sclerosis-associated interstitial lung disease : A case report and a literature review.

Liangyu Chen, Xiaoxuan Li, Donghui Huang, Peisheng Chen, Pan Xu, Huihui Chen, Xiao Zhang

Erratum issuedAbstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Zeitschrift fur Rheumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Liangyu ChenFaculty of Chinese Medicine, Macau University of Science and Technology, 999078, Macau, China.
Xiaoxuan LiDepartment of Rheumatology, The Eighth Affiliated Hospital of Sun Yat-sen University, 518000, Shenzhen, China.
Donghui HuangDepartment of Respiratory and Critical Care Medicine, Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine, 519000, Zhuhai, China.
Peisheng ChenDepartment of Respiratory and Critical Care Medicine, Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine, 519000, Zhuhai, China.
Pan XuDepartment of Respiratory and Critical Care Medicine, Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine, 519000, Zhuhai, China.
Huihui ChenFaculty of Chinese Medicine, Macau University of Science and Technology, 999078, Macau, China.
Xiao ZhangFaculty of Chinese Medicine, Macau University of Science and Technology, 999078, Macau, China. xiao_zhang26@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic sclerosis (SSc) is a rare autoimmune disease distinguished by fibrosis in the skin and internal organs. Interstitial lung disease (ILD) is a common manifestation of SSc and a major cause of death. Progressive SSc-ILD is a worsening form of SSc-ILD, indicating further development of the disease and a poor prognosis. Although significant progress has been made in the treatment of SSc-ILD in recent years, many issues and challenges remain, especially for progressive SSc-ILD. This paper aims to present a case of combination therapy using mycophenolate mofetil (MMF), nintedanib, and tocilizumab in a patient with progressive SSc-ILD. It is hoped that this case report will provide a reference for clinical practice and promote further studies.

Indexed as

Antibodies, Monoclonal, HumanizedIndolesLung Diseases, InterstitialMycophenolic AcidScleroderma, SystemicDrug Therapy, CombinationHumansImmunosuppressive AgentsTreatment OutcomeAntibodies, Monoclonal, HumanizedImmunosuppressive AgentsIndolesMycophenolic AcidnintedanibtocilizumabAutoimmune diseasesConnective tissue diseasesFibrosisRespiratory function testsSystemic sclerosis

Identifiers

PMID41784806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.